You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Nordisk
since
auto-detected in 129 stories
2 days ago
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
7 days ago
Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S. ⊕
Novo's approach to global launches will be guided by patient demand and the strength of healthcare and telehealth infrastructure, the drugmaker said.
23 days ago
Novo Nordisk’s next obesity battlefront: Winning beyond America ⊕
The weight loss pill had a strong U.S. launch this year, and Novo believes that will be replicated in other markets around the world.
29 days ago
Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight ⊕
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
35 days ago
Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals ⊕
Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.
Novo Nordisk CEO: Aim is to expand weight-loss market in U.S. ⊕
found
a story from CNBC ⚠️ › World News
Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales.
Novo Nordisk lifts forecasts after strong demand for Wegovy weight-loss pill ⊕⊕
found
a story from Financial Times ✅ › Financial Times
Shares in Danish drugmaker surge on positive signal from results
Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance ⊕
Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.
37 days ago
Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance ⊕
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
57 days ago
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount ⊕⊕
The partnership will enable Novo to better use AI to analyze complex datasets, and identify promising new drugs.